In this study, clinical manifestations of adverse events and frequently used medications in patients receiving parenteral nutrition (PN) in Korea were evaluated using Korea Adverse Event Reporting System (KAERS) database records between 2011 and 2015. Amino acids, fat emulsions, carbohydrates, combinations and solutions for PN were identified as causative agents. Adverse events classified as "certain", "probable" and "possible" based on the WHO-Uppsala Monitoring Centre criteria were analysed. In total, 6439 adverse events from 4260 patients were included for analysis. Mean patient age was 54.4 ± 18.1 years and the mean number of adverse events per patient was 1.5 ± 1.1. Frequent adverse events were gastrointestinal (2159 events, 33.5%), skin/appendage (1344 events, 20.9%), general (846 events, 13.1%) and central/peripheral nervous system (716 events, 11.1%) disorders. Common clinical symptoms were nausea (1248 events, 19.4%), vomiting (558, 8.7%), pruritus (456 events, 7.1%), rash (386 events, 6.0%) and dizziness (329 events, 5.1%). The frequently reported concomitant agents were tramadol (n = 475, 3.1%), fentanyl (n = 405, 2.7%), paracetamol (n = 329, 2.2%), ketorolac (n = 322, 2.1%) and metoclopramide (n = 289 cases, 1.9%). The frequent adverse events remained consistent after accounting for concurrent medications. Our findings from a nationwide reporting system database found that gastrointestinal disorders (nausea and vomiting) were the leading adverse events, requiring further studies on their prevalence, mechanisms and therapeutic options.
| INTRODUCTION
Nutritional support that provides adequate nutrition to malnourished patients is an important part of patient care for numerous medical conditions. They have been reported to have a number of positive impacts on clinical outcomes, including improved organ function, wound healing and immunity. 1, 2 Parenteral nutrition (PN) is a method to intravenously deliver nutritional supplements, which is essential for the survival of patients who are not able to obtain adequate nutrients through oral or enteral route. PN includes various nutrients that are necessary for the individual patient, such as carbohydrates, lipids, proteins, electrolytes, trace elements and vitamins. 3, 4 PN is widely used in indicated patients (ie, malnourished patients who are contraindicated for enteral nutrition (EN) or do not tolerate adequate EN). 5 A multicentre, cross-sectional study, comprising 300 patients in 25 hospitals in Korea, in 2014, revealed that the prevalence of malnutrition in the hospitalized patients was approximately 22.0%. Malnutrition was associated with a significant increase in the length of hospital stay and a low 90-day survival rate. The provision of appropriate nutritional therapy, in the form of PN or EN, 6 should be considered for malnourished patients. However, PN-related adverse events can occur. The wellknown adverse events associated with PN include mechanical adverse effects, such as catheter occlusion and catheterrelated infections, metabolic disorders, such as hyperglycaemia and hypertriglyceridaemia and infections. 7, 8 The administration of intravenous lipid emulsions and excessive carbohydrates may increase the risk of hypertriglyceridaemia, hypercholesterolaemia, hyperglycaemia and cholestasis. [8] [9] [10] In addition, intravenous injection of amino acids may induce increase in blood urea nitrogen (BUN), metabolic alkalosis, hyperammonemia, stupor and coma, especially in patients with renal or hepatic insufficiency. Although many reports of PN-related adverse events have been published, most of them have focused on specific complications (ie, infectious complications, refeeding syndrome) and mainly come from patients receiving PN in the acute care setting. 11 Furthermore, despite many anecdotal reports of nausea and vomiting in PN recipients, those complications have not been sufficiently addressed in the scientific literature. Korea Adverse Event Reporting System (KAERS) is a spontaneous adverse event reporting system that has been regulated by the Korea Institute of Drug Safety & Risk management (KIDS). 12 KAERS records are formed from adverse drug events reports submitted to KAERS via paper forms, telephone, fax or electronic forms on the KIDS website. 12 PN-related adverse events that occur in real-world setting can be broadly examined using this nationwide adverse event database, which may be able to detect neglected adverse events.
In the present study, we analysed adverse events in patients receiving PN using 5-year data in the KAERS database. Concomitant medications among the patients experiencing PN-related adverse events were also examined to account for effects from medications other than PN.
| MATERIALS AND METHODS

| Database and study drugs
Korea Adverse Event Reporting System (KAERS) data from patients who reported adverse events due to PN from 2011 to 2015 were analysed. Patient records in KAERS were anonymised and de-identified prior to analysis. The Institutional Review Board of Sookmyung Women's University approved this study (IRB No. SMWU-1701-HR-106) and waived the requirement for informed consent.
Korean Adverse Event Reporting System is a national spontaneous reporting system for adverse events (AEs) implemented in Korea and managed by the Korea Institute of Drug Safety and Risk Management (KIDS). AEs are generally reported through regional pharmacovigilance centres, which include hospitals, community pharmacies, pharmaceutical companies and patients, via paper forms, the telephone or the KIDS website. The AEs are reviewed, the completeness of the report is checked, and the causality of medications is evaluated by healthcare professionals at regional pharmacovigilance centres. These systematically reviewed AE reports are then submitted to the KAERS database and are available to researchers. The KAERS database is composed of the following six sections: general information, including reporting year; occurrence of serious adverse events; the patient's sex, age and concurrent disease; drug information containing ATC codes, drugs, indications, administration date and drug-related action taken after AEs; adverse drug reaction information; serious adverse event information; reporter information; and causality evaluation information. 13 The following Anatomical Therapeutic Chemical (ATC) codes were collected: B05BA (solutions for PN), B05BA01 (amino acids), B05BA02 (fat emulsions), B05BA03 (carbohydrates), B05BA04 (protein hydrolysates), B05BA10 (combinations). Only adverse events classified as "certain", "probable" and "possible" based on the causality assessment criteria of the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) were included. 14 
| Adverse event assessment
Clinical manifestations of PN adverse events were analysed and classified using the World Health Organization-adverse reaction terminology (WHO-ART) system. 15 System organ classes and preferred terms of the WHO-ART system were used as the main category and subcategories, respectively. Symptoms matched with the same preferred terms were treated as the same event. Two or more preferred terms reported in the same patient were counted as different adverse events. Serious adverse events were defined as cases that were fatal, caused hospitalisation, persistent disability or were life-threatening, according to the WHO criteria. 16 PN-related adverse events were first examined in the total sample (n = 4260). Then, patients were classified into three age groups: children (age <18 years, n = 168), adults (age 18-64 years, n = 2603) and older people (age ≥65 years, n = 1350). Concurrent medications were examined among all patients, and common adverse events (incidence ≥10%) of top concurrent medications were identified based on their FDA-approved label. 17 In case concomitant medications are associated with most frequent adverse events that we observed from PN, clinical manifestations of PN adverse events were again analysed in the subsets of patients not receiving such agents. Table 1 . Adverse events were most frequently reported for amino acids (2449 events, 38.0%), followed by combinations (2189 events, 34.0%) and fat emulsions (1435 events, 22.3%). The results were similar across age groups, except that amino acid products were more common PN agents in adults and elderly compared with children, whereas carbohydrate products were the most common in children (P =< 0.05). Related PN agents used in all patients and each age group are presented in Table 2 .
Commonly reported system organ adverse event classes related to PN use were gastrointestinal (2159 events, 33.5%), skin/appendage (1344 events, 20.9%), general (846 events, 13.1%) and central/peripheral nervous system (716 events, 11.1%) disorders with similar distribution across age groups, except in children. Skin/appendage disorders (66 events, 27.6%) and liver/biliary system disorders (18 events, 7.5%) were more frequent in children than in adults and older patients (Table 3) .
Commonly observed clinical symptoms are shown in Table 4 . Nausea (1248 events, 19.4%), vomiting (558 events, 8.7%), pruritus (456 events, 7.1%), rash (386 events, 6.0%) and dizziness (329 events, 5.1%) were the common clinical symptoms occurring due to PN-related adverse events. Adverse events classified by preferred terms were similar among age groups, except in children.
Urticaria (21 events, 6.1%) was the second most frequent clinical symptom in children.
We analysed the distribution of AEs by type in different PN solutions of amino acids, fat emulsions, carbohydrates or a combination of these; the results are shown in Tables 5 and 6 . Out of 2159 gastrointestinal system adverse events identified, the majority were related to the administration of amino acids (942 events, 43.6%) or combinations (730 events, 33.8%). Amino acid solutions were also the most frequent causative agent for nausea (584 events, 46.8%) and vomiting (252 events, 45.2%). It was noteworthy that most heart rate and rhythm adverse events were associated with amino acid products (61 events, 53.5%), as were palpitation (44 events, 60.3%) and chest pain (135 events, 54.2%). On the other hand, the majority of liver and biliary system adverse events and metabolic and nutritional adverse events occurred in patients received combination products (105 events, 66.9% and 56 events, 58.9%, respectively), with 80.3% of elevated hepatic enzymes and 80.6% of hyperglycaemia cases being accounted for by combination products.
The information on concurrent medications with PN was available for only 30% of patients. The frequently reported concomitant agents were tramadol (n = 475, 3.1%), fentanyl (n = 405, 2.7%), paracetamol (n = 329, 2.2%), ketorolac (n = 322, 2.1%) and metoclopramide (n = 289 cases, 1.9%) ( Table 7) . Among the common concurrent medications, tramadol, fentanyl, ketorolac, acetylcysteine, ambroxol and metronidazole were found to be strongly associated with nausea and vomiting (incidence ≥10%). 17 In particular, cetuximab-associated GI AEs were reported by more than 50% of patients. For the subsets of patients not receiving fentanyl (n = 3985), ketorolac (n = 4011), tramadol (n = 4058) or any of these three medications (n = 3784), nausea and vomiting were still the most commonly reported adverse events from PN; moreover, the percentages of the most common adverse events remained fairly consistent (Table 8 ).
| DISCUSSION
Adverse events are a major problem in patient care, increasing morbidity and mortality. [18] [19] [20] They are usually detected during clinical trials; however, small sample sizes, the relatively short duration of studies and the limited selection of patients can interfere with their detection during clinical trials. 21, 22 Therefore, a postmarketing pharmacovigilance system is implemented to improve patient safety analysis. Spontaneous adverse event reporting is used to detect unknown adverse events after a medication is approved. The postmarketing surveillance of medications is important to identify adverse events, compensating for the limited potential of clinical trials for detecting adverse events. 22, 23 To our knowledge, this is the first study to evaluate PN-related adverse events using a nationwide adverse event database from KAERS. Despite the frequent use of PN, studies on complications or adverse events related to PN use are lacking in clinical practice. This study analysed adverse events associated with PN use after classifying them by system organ class, accounting for causality, age distribution and concurrent medications. Although wellknown adverse events related to PN use include catheter occlusion, infections and metabolic disorders, our findings suggest that most frequent adverse events associated with PN use were gastrointestinal disorders (nausea and vomiting) and skin diseases (skin rash and itching). Because we used KAERS data collected over 5 years throughout Korea, results of this study reflect real-world data in current Korean clinical practice.
Patients experiencing nausea and vomiting while receiving PN are frequently observed in clinical practice. While nausea and vomiting are often considered as trivial adverse events, they are very inconvenient for patients, sometimes leading to discontinuation of PN. However, those symptoms have not gained much attention to be studied. One previous study in paediatric patients receiving home PN also reported that nausea and vomiting are common adverse events associated with PN, with 66% patients complaining of those symptoms. 24 Our findings from a nationwide reporting system database are consistent with the anecdotal experience and a previous report. 24 In our study, specific AEs occurred more frequently in the children and elderly owing to certain PN solutions. Our results showed that children experienced AEs more frequently with carbohydrates and less frequently with amino acids. To maintain growth rates, the relative protein requirement per body-weight is higher in children than adults. 25 Therefore, the provision of amino acids should be prioritized when considering PN requirements. Some reviews have addressed issues related to the possibility of excessive carbohydrates arising from interindividual differences in energy requirements. 26 Thus, excess carbohydrate may occur more frequently than amino acid and may have affected the outcome of this study. In our study, children were vulnerable to specific AEs, such as urticaria and angioedema. Urticaria, often characterized by the development of angioedema, is a common skin disease. 27 Acute urticaria occurs more often in children and is linked with IgE-mediated reactions. 28 A previous study that compared AEs by age in Korea suggested that urticaria was the most common AE in children, and headache and dizziness were the least frequent AEs. 29 Children with an immature immune system may be at risk of urticaria and angioedema. Physiological changes, such as the loss of subcutaneous fat and skin thinning, can occur in the elderly; moreover, the lack of these supporting tissues may increase the potential risk of phlebitis. 30 In a previous study, the incidence of phlebitis was reported to increase with age, especially in patients over the age of 60. 31 Rigour is one of clinical manifestation of bacteraemia. 32 In general, infections were more frequent in elderly patients than in adults because of comorbid illnesses, exposure to procedures and poor performance status. 33 The most commonly used medications along with PN in patients reporting adverse events were fentanyl (275 cases), ketorolac (249 cases) and tramadol (202 cases), all of which commonly cause nausea and vomiting. 17 While we examined the influence of those agents by subgroup analyses, it is difficult to rule out the possibility of concomitant medications confounding the findings. The results of subgroup analyses should be interpreted within the context that all concurrent medications may not be included in the selfreported data. Nonetheless, percentages of nausea and vomiting in the total sample and each subgroup remained consistent, suggesting nausea and vomiting may be frequently caused by PN itself rather than other medications received along with PN. The mechanisms of nausea and vomiting caused by PN remain unknown and require further investigation. Possible explanations include decreased gastrointestinal motility and liver engorgement. 34 PN is well known to reduce GI motility, and delayed gastric emptying from slow GI motility has been shown to cause nausea. 35 Intravenous glucose is mainly consumed by liver and less by skeletal muscle in immobilized patients. This may possibly cause liver engorgement, resulting in nausea and vomiting. 34 In this study, the most frequently reported adverse events were related to the use of amino acids (38%), followed by combinations (34%) and fat emulsions (22.3%). It is possible that adverse event incidence for each solution correlates with the incidence of each solution used. However, KIDS-KD used in this study included only adverse event data, and we could not obtain data related to PN use in Korea, at present. Additionally, amino acid products were the most frequent causative agent for heart rate and rhythm disorders, whereas the majority of hepatic and metabolic adverse events were related to the administration of combination products. The FDA product labellings for amino acid intravenous solutions state that metabolic acidosis and alkalosis related to the use of amino acid products have been reported from clinical studies as well as voluntary reports, which may result in chest pain and palpitations. 17 Since one of the major risk factors for PNassociated liver disease is excessive calories, 36 combination products with a higher chance of overfeeding may cause hepatic adverse events and hyperglycaemia more than individual nutrient solutions. Yet again, given the limitation of the data, it is difficult to draw a definite relationship between specific PN solutions and specific adverse events based on the present findings. Further studies are required to analyse adverse events of PN based on its use. In Korea, the Nutrition Support Team (NST), composed of physicians, nurses, dietitians and pharmacists, takes part in nutritional assessment, appropriate PN or enteral nutrition use in malnourished patients in hospitals, and monitors their complications. Several previous studies have shown that NST interventions have a positive effect on clinical outcomes in patients. 37, 38 In our study, rare but serious adverse events, such as dyspnoea and anaphylaxis, accounted for 3% of all adverse events. Therefore, the monitoring of clinical symptoms of patients and active interventions by NST can prevent PN-related adverse events and improve the effectiveness and safety of PN use. This study has several limitations that need to be considered when interpreting the findings. Because this study was based on spontaneous adverse event reports, underreporting could be possible. Acute adverse events occurring at the beginning of PN administration could be relatively well detected and reported; however, chronic or delayed adverse events are a limiting factor in assessing the causality or reporting of adverse events. Nonetheless, PN-related adverse events were generally reported by healthcare providers (83% by physicians, nurses and pharmacists in our data), and under-reporting is a less severe concern than it is when analysing spontaneous adverse event reports from both healthcare professionals and patients. Secondly, the retrospective nature of the study and using the secondary data limited the ability to establish causal relationships and prevented us from examining additional variables that are known to be significant factors associated with PN-related adverse events, such as comorbid conditions. Thirdly, in this study, concomitant medication was not reported in approximately 70% of patients with PN, which can affect specific AEs associated with PN. The possibility of under-reporting of concomitant medication is inevitable and is another limitation of this study. Conversely, some medications, such as cetuximab, result in a high incidence (>50%) of GI AEs and thus the incidence of PN AEs cannot be established in patients receiving these medications.
In this study, we analysed National Pharmacovigilance data reported in all regions of Korea, and the results represent PN-related adverse events along with those of concomitant medications in real clinical practice. These results can be used to prospectively study PN adverse events or perform long-term cohort analysis. They will also help healthcare providers anticipate, detect and respond appropriately to complications or adverse events that may occur in patients receiving PN.
In conclusion, we analysed KAERS PN data from 2011 to 2015 and showed that gastrointestinal (nausea and vomiting) and skin (pruritus) disorders were most frequent adverse events. After accounting for effects of concurrent medications, nausea and vomiting were still most frequent adverse events. While it is difficult to rule out the potential confounding effect of concomitant medications and comorbid conditions, our findings support frequent reports of nausea and vomiting in PN recipients observed in clinical practice. Further studies to better understand the prevalence, mechanisms and therapeutic options for PN-related nausea and vomiting are warranted. 
